Summary
Stryker Corporation's first quarter 2009 report indicates a slight decrease in net sales compared to the prior year, primarily impacted by unfavorable foreign currency exchange rates. Despite this, the company managed to increase its operating income on a constant currency basis, driven by strong performance in its Orthopaedic Implants segment. However, the MedSurg Equipment segment experienced a sales decline, particularly in patient handling and emergency medical equipment. The company is navigating a challenging economic environment, leading to a reduction in its full-year 2009 earnings guidance. This is attributed to weaker demand for certain products and a slowdown in elective procedures. Significant ongoing legal and regulatory matters, including investigations into its Stryker Biotech subsidiary and FDA warning letters, continue to be disclosed and are being addressed by management. The company maintains a strong liquidity position with substantial cash and marketable securities.
Financial Highlights
26 data points| Revenue | $1.60B |
| Cost of Revenue | $515.50M |
| Gross Profit | $1.09B |
| R&D Expenses | $80.40M |
| SG&A Expenses | $616.60M |
| Operating Expenses | $706.60M |
| Operating Income | $379.20M |
| Net Income | $281.10M |
| EPS (Basic) | $0.71 |
| EPS (Diluted) | $0.71 |
| Shares Outstanding (Basic) | 396.70M |
| Shares Outstanding (Diluted) | 398.60M |
Key Highlights
- 1Net sales for the first quarter of 2009 decreased by 2% to $1,601.3 million, impacted by a 5% unfavorable foreign currency exchange rate effect. On a constant currency basis, net sales increased by 3%.
- 2Orthopaedic Implants segment sales remained flat year-over-year at $973.2 million, but showed a 6% increase on a constant currency basis, driven by strong performance in reconstructive, trauma, and spinal implant systems.
- 3MedSurg Equipment segment sales decreased by 5% to $628.1 million, with a 1% decrease on a constant currency basis, negatively impacted by lower sales in patient handling and emergency medical equipment.
- 4Operating income remained stable at $379.2 million, with operating margin increasing slightly to 23.7% from 23.5% in the prior year, reflecting effective cost management despite lower sales.
- 5The company reduced its full-year 2009 diluted net earnings per share guidance to a range of $2.90 to $3.10, reflecting anticipated weaker demand and a slowdown in elective procedures.
- 6Stryker reported $685.8 million in cash and cash equivalents and $1,559.3 million in marketable securities as of March 31, 2009, indicating a strong liquidity position.
- 7The company disclosed ongoing legal and regulatory matters, including a federal grand jury investigation into its Stryker Biotech subsidiary and FDA warning letters related to manufacturing facilities.